TriSalus Life Sciences, Inc. (TLSI, Financial) reported first-quarter revenue of $9.17 million, surpassing the projected estimate of $9.04 million. This strong performance is attributed to the increasing effectiveness of their Pressure-Enabled Drug Delivery (PEDD) platform, which is utilized in treating various solid tumor indications.
Mary Szela, President and CEO of TriSalus, highlighted their strategic advancements, including the partnership decision for the development of Nelitolimod post-Phase 1 trials and the expansion of their TriNav portfolio to cover a broader range of applications. These developments position the company favorably to advance its long-term strategic objectives.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for TriSalus Life Sciences Inc (TLSI, Financial) is $11.44 with a high estimate of $16.00 and a low estimate of $10.00. The average target implies an upside of 133.42% from the current price of $4.90. More detailed estimate data can be found on the TriSalus Life Sciences Inc (TLSI) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, TriSalus Life Sciences Inc's (TLSI, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
